Derma Sciences Provides Update on Aclerastide Phase 3 Trials

PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, reports the halfway point of enrollment in the Phase 3 program with aclerastide (DSC127) in subjects with diabetic foot ulcers. The clinical trial sites contributing at this time are from the U.S. (including Puerto Rico), Canada and South Africa. The Company is taking solid steps toward accelerating screening and enrollment by opening additional sites in Eastern Europe, Germany and potentially Israel.